The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...
Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access ...
The CRISPR-based gene therapy Casgevy (exagamglogene autotemcel) has been made available to patients with sickle cell disease in England, following positive guidance issued by the National ...
The biotech's Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed with Vertex Pharmaceuticals, is now approved in the U.S ...
What Casgevy does is turn a patient’s own cells, already a perfect match, into a transplant. Doctors harvest stem cells from the patient’s bone marrow and then send them off to a lab ...
More than 50 authorized treatment centers (ATCs) activated globally for CASGEVY, and more than 50 patients have had cells collected across all regions as of the end of 2024- -Clinical trials ...
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback